SSA
IDXG

Schonfeld Strategic Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40,000
Closed -$320K – 1373
2019
Q1 		$320K Sell
40,000
-40,000
-50% -$376K 0.01% 818
2018
Q4 		$640K Sell
80,000
-20,000
-20% -$240K 0.02% 589
2018
Q3 		$1.54M Buy
100,000
+77,500
+344% +$934K 0.07% 338
2018
Q2 		$200K Buy
+22,500
New +$199K 0.01% 704

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Schonfeld Strategic Advisors's IDXG Position: Q2 2019 in Review

Schonfeld Strategic Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2019, closing a stake of 40,000 shares — an estimated $320K sold.

Schonfeld Strategic Advisors first reported a position in IDXG in Q2 2018 and held it in 4 quarters. The position peaked at $1.54M in Q3 2018. 18 funds tracked by Wall St. Rank hold IDXG as of Q2 2019.

  • Schonfeld Strategic Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 40,000 Interpace Biosciences, Inc. Common Stock shares in Q2 2019, an estimated $320K.
  • Schonfeld Strategic Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $1.54M in Q3 2018.
  • 18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.